therapeutic development

Bispecific antibodies (bsAbs) are an important addition to the immuno-oncology toolbox. Designed to recognize two distinct epitopes, bsAbs have enhanced binding, specificity, and efficacy compared to current monovalent antibody therapeutics, making them exciting candidates for more targeted cancer treatments. Learn about bsAbs and how our tools can help scientists with their research on therapeutic candidates.

Adeno-associated viruses (AAVs) are some of the most commonly used viral vectors for gene therapy, supporting approximately 250 clinical trials to date. However, the manufacturing processes are challenging to scale. Read about five key issues that gene therapy manufacturers who use AAVs need to look out for.